Generic Medicine Info
Known or suspected sex-steroid sensitive malignancies, undiagnosed vaginal bleeding, active venous thromboembolic disorder, acute porphyria. Severe hepatic impairment (active or history). Pregnancy.
Special Precautions
Women with breast cancer, liver cancer, functional ovarian cyst; hypertension, history of thromboembolic disorders, previous ectopic pregnancy; diabetes mellitus, severe gastrointestinal disturbances, SLE with positive (or unknown) antiphospholipid antibodies; depression, migraine; history of chloasma gravidarum. Women undergoing prolonged immobilisation due to surgery or illness. Mild to moderate hepatic impairment. Lactation. Monitoring Parameters Screen for pregnancy and perform diagnostic measures for bleeding disturbances (e.g. amenorrhoea, oligomenorrhoea) before initiating treatment. Monitor for amenorrhoea or abdominal pain as it must be considered for the differential diagnosis of ectopic pregnancy; signs and symptoms of depression and breakthrough bleeding.
Adverse Reactions
Significant: Breakthrough bleeding, venous thromboembolism (e.g. DVT, pulmonary embolism), hypertension, SLE, porphyria, chloasma; depressed mood and depression. Eye disorders: Contact lens intolerance. Gastrointestinal disorders: Nausea, vomiting. General disorders and administration site conditions: Fatigue. Investigations: Increased weight. Nervous system disorders: Headache. Pregnancy, puerperium and perinatal conditions: Rarely, ectopic pregnancy. Psychiatric disorders: Mood alterations. Reproductive system and breast disorders: Breast pain, irregular menstruation, amenorrhoea, dysmenorrhoea, ovarian cyst, decreased libido. Skin and subcutaneous tissue disorders: Acne, alopecia.
Drug Interactions
Decreased contraceptive efficacy with enzyme inducers (e.g. barbiturates, bosentan, carbamazepine, phenytoin, primidone, rifampicin, efavirenz, felbamate, griseofulvin, oxcarbazepine, topiramate, and rifabutin). May increase the plasma concentrations with CYP3A4 inhibitors (e.g. ketoconazole, erythromycin, diltiazem). May increase or decrease the plasma concentrations with HIV protease inhibitors (e.g. ritonavir), agents for hepatitis C virus (e.g. boceprevir), and non-nucleoside reverse transcriptase inhibitors (e.g. nevirapine). May increase the plasma and tissue levels of ciclosporin. May decrease the plasma and tissue levels of lamotrigine.
CIMS Class
ATC Classification
G03AC09 - desogestrel ; Belongs to the class of progestogens. Used as systemic contraceptives.
Disclaimer: This information is independently developed by CIMS based on desogestrel from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in